Log in with your email address username.


[Correspondence] ANTARCTIC: platelet function testing to adjust therapy

We carefully read the ANTARCTIC study by Guillaume Cayla and colleagues (Oct 22, p 2015),1 and would like to suggest a different interpretation of the results. The trial studied the utility of platelet function reactivity (assessed by VerifyNow) guidance in elderly patients (aged ≥75 years) with acute coronary syndrome and ST-elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention and were treated with prasugrel 5 mg daily. For power calculations, the investigators used a combined endpoint of ischaemic and bleeding events, and bleeding events drove the overall event rates.